Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics (NASDAQ: IMTX), a biopharmaceutical company focused on developing T cell-based cancer immunotherapies, announced it will present data on its lead product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 ASCO Annual Meeting in Chicago, Illinois, from May 30 – June 3, 2025.

An oral presentation will feature updated Phase 1b trial data for IMA203 in metastatic melanoma patients. This data includes a longer follow-up period compared to the presentation in October 2024, as well as data from additional uveal melanoma patients enrolled since then.

A poster presentation will provide an update on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have previously been treated with a checkpoint inhibitor.

Abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET.

Oral Presentation

Title: Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma
Presenting author: Martin Wermke, MD
Session: Developmental Therapeutics – Immunotherapy
Date / Time: May 31, 2025 / 3:00 – 6:00 pm CDT
Abstract ID: 2508

Poster Presentation

Title: SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma
Presenting author: Jason Luke, MD, FACP, FASCO
Session: Developmental Therapeutics – Immunotherapy
Date / Time: June 2, 2025 / 1:30 – 4:30 pm CDT
Abstract ID: TPS2673

About IMA203 TCR T-cell Therapy and Target PRAME
IMA203 is an engineered autologous T-cell receptor T-cell therapy (TCR T) targeting PRAME, an intracellular protein presented as a peptide antigen on the surface of various solid tumors via HLA-A*02:01. It exhibits minimal expression on healthy tissues. With its precise targeting and a roughly 14-day turnaround time, IMA203 has shown a promising clinical profile for patients with significant unmet medical needs.

The registration-enabling, randomized, controlled Phase 3 “SUPRAME” trial is currently evaluating IMA203 TCR T-cell therapy in patients with unresectable or metastatic cutaneous melanoma that has progressed after treatment with at least one PD-1 inhibitor. The Phase 1b clinical trial in patients with solid tumors expressing PRAME is also ongoing, with a focus on uveal melanoma.

About Immatics
Immatics leverages its expertise in identifying true targets for cancer immunotherapies and developing effective T-cell receptors to generate specific and robust T-cell responses against these targets. This knowledge fuels our pipeline of Adoptive Cell Therapies and TCR Bispecifics, as well as our collaborations with leading pharmaceutical companies. We are dedicated to harnessing the power of T cells to create new treatment options for cancer patients.

Immatics plans to use its website as a channel for disseminating important non-public information. Stay updated by following us on and .

For more information, please contact:

Media
Trophic Communications
Phone: +49 151 74416179

Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325

Attachment

“`